80 FR 63626 - Accentia Biopharmaceuticals, Inc. and Biostem U.S. Corp., Order of Suspension of Trading

SECURITIES AND EXCHANGE COMMISSION

Federal Register Volume 80, Issue 202 (October 20, 2015)

Page Range		63626-63627
FR Document		2015-26722

Federal Register, Volume 80 Issue 202 (Tuesday, October 20, 2015)

[Federal Register Volume 80, Number 202 (Tuesday, October 20, 2015)]
[Notices]
[Pages 63626-63627]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-26722]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]


Accentia Biopharmaceuticals, Inc. and Biostem U.S. Corp., Order 
of Suspension of Trading

October 16, 2015.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Accentia Biopharmaceuticals, Inc. (CIK No. 1310094), a dissolved 
Florida corporation with its principal place of business listed as 
Tampa, Florida, with stock quoted on OTC Link (previously, ``Pink 
Sheets'') operated by OTC Markets Group, Inc. (``OTC Link'') under the 
ticker symbol ABPI, because it has not filed any periodic reports since 
the period ended December 31, 2012. On October 27, 2014, Accentia 
Biopharmaceuticals received a delinquency letter sent by the Division 
of Corporation Finance requesting compliance with their periodic filing 
obligations.

[[Page 63627]]

    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Biostem U.S. Corp. (CIK No. 1455380), a revoked Nevada corporation with 
its principal place of business listed as Clearwater, Florida, with 
stock quoted on OTC Link under the ticker symbol HAIR, because it has 
not filed any periodic reports since the period ended November 30, 
2012. On November 7, 2014, the Division of Corporation Finance sent 
Biostem U.S. a delinquency letter requesting compliance with their 
periodic filing obligations, but the letter was returned because of 
Biostem U.S.'s failure to maintain a valid address on file with the 
Commission, as required by Commission rules (Rule 301 of Regulation S-
T, 17 CFR 232.301 and Section 5.4 of EDGAR Filer Manual).
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed companies.
    Therefore, it is ordered, pursuant to Section 12(k) of the 
Securities Exchange Act of 1934, that trading in the securities of the 
above-listed companies is suspended for the period from 9:30 a.m. EDT 
on October 16, 2015, through 11:59 p.m. EDT on October 29, 2015.

    By the Commission.
Brent J. Fields
Secretary.
[FR Doc. 2015-26722 Filed 10-16-15; 11:15 am]
 BILLING CODE 8011-01-P

63626 Federal Register / Vol. 80, No. 202 / Tuesday, October 20, 2015 / Notices

2. Statutory Basis thereunder.15 The proposed rule change amendments, all written statements
The Exchange believes that proposed effects a change that (A) does not with respect to the proposed rule
rule change is consistent with Section significantly affect the protection of change that are filed with the
6(b)(5) of the Act,12 which requires, investors or the public interest; (B) does Commission, and all written
among other things, that the Exchange’s not impose any significant burden on communications relating to the
rules be designed to prevent fraudulent competition; and (C) by its terms, does proposed rule change between the
and manipulative acts and practices, to not become operative for 30 days after Commission and any person, other than
promote just and equitable principles of the date of the filing, or such shorter those that may be withheld from the
trade, to foster cooperation and time as the Commission may designate public in accordance with the
coordination with persons engaged in if consistent with the protection of provisions of 5 U.S.C. 552, will be
facilitating transactions in securities, investors and the public interest; available for Web site viewing and
and to remove impediments to and provided that the self-regulatory printing in the Commission’s Public
perfect the mechanism of a free and organization has given the Commission Reference Room, 100 F Street NE.,
open market and a national market written notice of its intent to file the Washington, DC 20549, on official
system. The Exchange believes that the proposed rule change, along with a brief business days between the hours of
proposed rule change will further these description and text of the proposed 10:00 a.m. and 3:00 p.m. Copies of such
requirements by providing greater rule change, at least five business days filing will also be available for
harmonization between Exchange and prior to the date of filing of the inspection and copying at the principal
FINRA rules of similar purpose, proposed rule change, or such shorter office of the Exchange. All comments
resulting in greater uniformity and less time as designated by the Commission. received will be posted without change;
burdensome and more efficient At any time within 60 days of the the Commission does not edit personal
regulatory compliance. As such, the filing of the proposed rule change, the identifying information from
proposed rule change would foster Commission may summarily submissions. You should submit only
cooperation and coordination with temporarily suspend such rule change if information that you wish to make
persons engaged in facilitating it appears to the Commission that such available publicly. All submissions
transactions in securities and would action is: (1) Necessary or appropriate in should refer to File No. SR–BYX–2015–
remove impediments to and perfect the the public interest; (2) for the protection 43 and should be submitted on or before
mechanism of a free and open market of investors; or (3) otherwise in October 23,2015.
and a national market system in furtherance of the purposes of the Act.
For the Commission, by the Division of
accordance with Section 6(b)(5) of the If the Commission takes such action, the Trading and Markets, pursuant to delegated
Act.13 Commission shall institute proceedings authority.16
to determine whether the proposed rule Robert W. Errett,
(B) Self-Regulatory Organization’s should be approved or disapproved.
Statement on Burden on Competition Deputy Secretary.
IV. Solicitation of Comments [FR Doc. 2015–26577 Filed 10–19–15; 8:45 am]
The Exchange does not believe that
the proposed rule change would impose Interested persons are invited to BILLING CODE 8011–01–P

any burden on competition that is not submit written data, views and
necessary or appropriate in furtherance arguments concerning the foregoing,
including whether the proposal is SECURITIES AND EXCHANGE
of the purposes of the Act. The
consistent with the Act. Comments may COMMISSION
proposed rule change is not designed to
address any competitive issues but be submitted by any of the following [File No. 500–1]
rather to provide greater harmonization methods:
among Exchange and FINRA rules of Accentia Biopharmaceuticals, Inc. and
Electronic Comments
similar purpose, resulting in less Biostem U.S. Corp., Order of
burdensome and more efficient • Use the Commission’s Internet Suspension of Trading
regulatory compliance for common comment form (http://www.sec.gov/
rules/sro.shtml); or October 16, 2015.
members and facilitating FINRA’s
• Send an email to rule-comments@ It appears to the Securities and
performance of its regulatory functions Exchange Commission that there is a
sec.gov. Please include File No. SR–
under the 17d–2 Agreement. lack of current and accurate information
BYX–2015–43 on the subject line.
(C) Self-Regulatory Organization’s concerning the securities of Accentia
Paper Comments Biopharmaceuticals, Inc. (CIK No.
Statement on Comments on the
Proposed Rule Change Received From • Send paper comments in triplicate 1310094), a dissolved Florida
Members, Participants or Others to Secretary, Securities and Exchange corporation with its principal place of
Commission, 100 F Street NE., business listed as Tampa, Florida, with
The Exchange has neither solicited
Washington, DC 20549–1090. stock quoted on OTC Link (previously,
nor received written comments on the
proposed rule change. All submissions should refer to File No. ‘‘Pink Sheets’’) operated by OTC
SR–BYX–2015–43. This file number Markets Group, Inc. (‘‘OTC Link’’) under
III. Date of Effectiveness of the should be included on the subject line the ticker symbol ABPI, because it has
Proposed Rule Change and Timing for if email is used. To help the not filed any periodic reports since the
Commission Action Commission process and review your period ended December 31, 2012. On
mstockstill on DSK4VPTVN1PROD with NOTICES

The Exchange has designated this rule comments more efficiently, please use October 27, 2014, Accentia
filing as non-controversial under only one method. The Commission will Biopharmaceuticals received a
Section 19(b)(3)(A) of the Act 14 and post all comments on the Commission’s delinquency letter sent by the Division
paragraph (f)(6) of Rule 19b–4 Internet Web site (http://www.sec.gov/ of Corporation Finance requesting
rules/sro.shtml). Copies of the compliance with their periodic filing
12 15 U.S.C. 78f(b)(5). submission, all subsequent obligations.
13 Id.
14 15 U.S.C. 78s(b)(3)(A). 15 17 CFR 240.19b–4. 16 17 CFR 200.30–3(a)(12).

VerDate Sep<11>2014 17:55 Oct 19, 2015 Jkt 238001 PO 00000 Frm 00129 Fmt 4703 Sfmt 4703 E:\FR\FM\20OCN1.SGM 20OCN1

Document Created: 2015-12-14 15:25:33
Document Modified: 2015-12-14 15:25:33

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
FR Citation		80 FR 63626